These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 39457485)

  • 1. Comprehensive High-Depth Proteomic Analysis of Plasma Extracellular Vesicles Containing Preparations in Rett Syndrome.
    Hagiwara S; Shiohama T; Takahashi S; Ishikawa M; Kawashima Y; Sato H; Sawada D; Uchida T; Uchikawa H; Kobayashi H; Shiota M; Nabatame S; Tsujimura K; Hamada H; Suzuki K
    Biomedicines; 2024 Sep; 12(10):. PubMed ID: 39457485
    [No Abstract]   [Full Text] [Related]  

  • 2. Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome.
    Neul JL; Percy AK; Benke TA; Berry-Kravis EM; Glaze DG; Peters SU; Jones NE; Youakim JM
    Contemp Clin Trials; 2022 Mar; 114():106704. PubMed ID: 35149233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative proteomic analysis of Rett iPSC-derived neuronal progenitors.
    Varderidou-Minasian S; Hinz L; Hagemans D; Posthuma D; Altelaar M; Heine VM
    Mol Autism; 2020 May; 11(1):38. PubMed ID: 32460858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is trofinetide a future treatment for Rett syndrome? A comprehensive systematic review and meta-analysis of randomized controlled trials.
    Mohammed HE; Bady Z; Haseeb ME; Aboeldahab H; Sharaf-Eldin WE; Zaki MS
    BMC Med; 2024 Jul; 22(1):299. PubMed ID: 39020317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of trofinetide for the treatment of Rett syndrome: from bench to bedside.
    Kennedy M; Glass L; Glaze DG; Kaminsky S; Percy AK; Neul JL; Jones NE; Tropea D; Horrigan JP; Nues P; Bishop KM; Youakim JM
    Front Pharmacol; 2023; 14():1341746. PubMed ID: 38318312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA sequencing and proteomics approaches reveal novel deficits in the cortex of
    Pacheco NL; Heaven MR; Holt LM; Crossman DK; Boggio KJ; Shaffer SA; Flint DL; Olsen ML
    Mol Autism; 2017; 8():56. PubMed ID: 29090078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need.
    Hudu SA; Elmigdadi F; Qtaitat AA; Almehmadi M; Alsaiari AA; Allahyani M; Aljuaid A; Salih M; Alghamdi A; Alrofaidi MA; Abida ; Imran M
    J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome.
    Darwish M; Passarell J; Youakim JM; Bradley H; Bishop KM
    Adv Ther; 2024 Apr; 41(4):1462-1480. PubMed ID: 38363467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trofinetide Treatment Demonstrates a Benefit Over Placebo for the Ability to Communicate in Rett Syndrome.
    Neul JL; Percy AK; Benke TA; Berry-Kravis EM; Glaze DG; Peters SU; Marsh ED; An D; Bishop KM; Youakim JM
    Pediatr Neurol; 2024 Mar; 152():63-72. PubMed ID: 38232652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.
    Neul JL; Percy AK; Benke TA; Berry-Kravis EM; Glaze DG; Marsh ED; Lin T; Stankovic S; Bishop KM; Youakim JM
    Nat Med; 2023 Jun; 29(6):1468-1475. PubMed ID: 37291210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trofinetide in Rett syndrome: A brief review of safety and efficacy.
    Singh A; Balasundaram MK; Gupta D
    Intractable Rare Dis Res; 2023 Nov; 12(4):262-266. PubMed ID: 38024580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A meta-analysis of the efficacy and safety of trofinetide in patients with rett syndrome.
    Abo Zeid M; Elrosasy A; Mohamed RG; Ghazou A; Goufa E; Hassan N; Abuzaid Y
    Neurol Sci; 2024 Oct; 45(10):4767-4778. PubMed ID: 38771525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome.
    Glaze DG; Neul JL; Kaufmann WE; Berry-Kravis E; Condon S; Stoms G; Oosterholt S; Della Pasqua O; Glass L; Jones NE; Percy AK;
    Neurology; 2019 Apr; 92(16):e1912-e1925. PubMed ID: 30918097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A proteomics approach to further highlight the altered inflammatory condition in Rett syndrome.
    Cicaloni V; Pecorelli A; Cordone V; Tinti L; Rossi M; Hayek J; Salvini L; Tinti C; Valacchi G
    Arch Biochem Biophys; 2020 Dec; 696():108660. PubMed ID: 33159892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives.
    Moore R; Poulsen J; Reardon L; Samples-Morris C; Simmons H; Ramsey KM; Whatley ML; Lane JB
    Adv Ther; 2024 Apr; 41(4):1305-1317. PubMed ID: 38378975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the Rett Syndrome Behaviour Questionnaire and its utilization in the assessment of symptoms associated with Rett syndrome.
    Percy AK; Neul JL; Benke TA; Marsh ED; Glaze DG
    Front Pediatr; 2023; 11():1229553. PubMed ID: 37635789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rett Syndrome: The Emerging Landscape of Treatment Strategies.
    Percy AK; Ananth A; Neul JL
    CNS Drugs; 2024 Nov; 38(11):851-867. PubMed ID: 39251501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study.
    Percy AK; Neul JL; Benke TA; Berry-Kravis EM; Glaze DG; Marsh ED; Barrett AM; An D; Bishop KM; Youakim JM
    Med; 2024 Oct; 5(10):1275-1281.e2. PubMed ID: 39025065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trofinetide: First Approval.
    Keam SJ
    Drugs; 2023 Jun; 83(9):819-824. PubMed ID: 37191913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rett Syndrome, a Neurodevelopmental Disorder, Whole-Transcriptome, and Mitochondrial Genome Multiomics Analyses Identify Novel Variations and Disease Pathways.
    Aldosary M; Al-Bakheet A; Al-Dhalaan H; Almass R; Alsagob M; Al-Younes B; AlQuait L; Mustafa OM; Bulbul M; Rahbeeni Z; Alfadhel M; Chedrawi A; Al-Hassnan Z; AlDosari M; Al-Zaidan H; Al-Muhaizea MA; AlSayed MD; Salih MA; AlShammari M; Faiyaz-Ul-Haque M; Chishti MA; Al-Harazi O; Al-Odaib A; Kaya N; Colak D
    OMICS; 2020 Mar; 24(3):160-171. PubMed ID: 32105570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.